Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $228.9 million.

  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) rose 2119.2% to $228.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.9 million, marking a year-over-year increase of 2119.2%. This contributed to the annual value of $200.2 million for FY2024, which is 1594.44% up from last year.
  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) amounted to $228.9 million in Q3 2025, which was up 2119.2% from $228.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $228.9 million during Q3 2025, with a 5-year trough of $158725.0 in Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $174.0 million, with a median of $170.6 million in 2023.
  • Over the last 5 years, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) had its largest YoY gain of 10953584.02% in 2021, and its largest YoY loss of 9989.4% in 2021.
  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $164.5 million in 2021, then increased by 3.22% to $169.8 million in 2022, then increased by 1.69% to $172.7 million in 2023, then grew by 15.94% to $200.2 million in 2024, then rose by 14.32% to $228.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $228.9 million in Q3 2025, compared to $228.4 million in Q2 2025 and $226.1 million in Q1 2025.